SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to positive news regarding its APU CIM architecture achieving GPU-class AI performance with significantly lower energy consumption, sparking community discussion about potential buyouts and comparisons to other AI and chip companies like NVDA. The community is actively debating whether the stock is primed for a short squeeze and discussing strategies to capture further upside. Some traders express concerns about potential dilution and the company's history, while others focus on the potential for long-term growth in the AI and edge computing sectors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as users report widespread platform outages, potentially linked to Amazon Web Services, sparking frustration and concerns about accessibility during trading. The community is debating the cause of the issues, with some questioning the reliability of the platform and others attributing it to broader internet service disruptions. Despite the technical difficulties, the stock price has shown surprising resilience, leading to discussions about market dynamics and potential manipulation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is trending due to news of FDA acceptance of its Biologics License Application resubmission, sparking optimism and driving discussions around potential price targets. Community members are actively debating the company's future prospects, with some highlighting new price targets and potential breakouts, while others express skepticism and point to potential shorting opportunities. The stock's collaborations and setup are also being closely watched by traders.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as investors discuss the implications of new data, with some citing a strong response rate in lung cancer patients from a GenFleet study. While some view the sell-off as an overreaction or manipulation, others question the long-term impact and management's spending. The community is actively debating the data's significance and comparing it to competitors in the KRAS G12D space.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth mineral production, potentially transforming it into a strategic metals player amid tightening export controls from China. This pivot is sparking discussions about the company's growth potential beyond steel, with some seeing it as a smart move while others question execution and debt. Community members are closely monitoring its Q3 earnings report to determine if it can meet expectations.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending due to its recent listing on Robinhood, generating excitement within the community; many anticipate a significant price surge following the listing. Community members are drawing comparisons to Dogecoin and Shiba Inu, while others are focused on long-term price predictions and utility.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as analysts debate the achievability of its ambitious long-term growth targets outlined during its Analyst Day, specifically regarding revenue and AI infrastructure spending. The community is actively discussing whether AI infrastructure investments will impact profitability, and some are drawing comparisons to past optimistic guidance from the company. Overall, sentiment appears mixed as investors weigh the potential for future growth against possible short-term financial strain.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the stock flirts with all-time highs, driven by positive sentiment around iPhone 17 sales and potential AI integration. Community discussions revolve around analyst upgrades, revenue projections, and the ongoing battle for AI talent with companies like Meta. Some investors express concerns about valuation and potential market corrections, while others remain bullish, anticipating a continued rally.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, EMEA and APAC. The Americas segment includes operations in North America and South America. The EMEA segment includes operations in Europe, the Middle East and Africa. The APAC segment includes operations in the Asia-Pacific region, including Asia and Oceania. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch is trending due to a recent sell-off, despite what some perceive as a strong underlying business and growth potential. Community members are actively debating whether the stock is oversold and a potential value play, with some pointing to a low forward P/E ratio and significant buyback authorization, while others cite concerns about tariffs and margin pressure.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending due to positive Phase 3 trial results for its breast cancer therapy, leading to analysts raising price targets and optimism for FDA approval. The community is actively discussing the potential for a buyout and the stock's strong institutional ownership, while some caution against hype and potential dilutions. Attention is also focused on the company's upcoming data releases and potential for market dominance in its sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Weekly Stock Market Update: Apple, Taiwan Semiconductor and Novo Nordisk

It was a volatile but ultimately positive week on Wall Street, marked by renewed tensions in the U.S.-China trade war and a strong start to the earnings season. Major banks exceeded expectations...

NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio

Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in...

Omeros’ stock had&nbsp;its best day on Wednesday ever after H.C. Wainwright raised its price target to $20 from $9 and kept a ‘Buy’ rating, following news of a multibillion-dollar licensing deal with Novo Nordisk for its rare disease drug candidate zaltenibart.<a href="https://stocktwits.com/symbol/OMER">Shares of Omeros</a> jumped 154.1% to close at $10.42 on Wednesday, before slipping 3.1% in after-hours trading, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed shares</a> edged up 0.1% to $54.06.The brokerage said Omeros will get $240 million upfront, along with up to $510 million in development and approval milestone payments and as much as $1.3 billion tied to future sales, plus royalties. H.C. Wainwright said the new target reflects the significant non-dilutive cash Omeros will receive and updated risk assumptions for zaltenibart.Under the agreement, Novo Nordisk will take full global control of developing and commercializing zaltenibart, which targets MASP-3, a key protein linked to several rare blood and kidney disorders. The deal could be worth as much as $2.1 billion if all milestones are met. Novo Nordisk said the medicine could become a best-in-class option and will help strengthen its rare disease business.Omeros CEO Gregory Demopulos said teaming up with Novo Nordisk allows the drugmaker to expand zaltenibart’s reach worldwide while Omeros focuses on bringing its own drug, narsoplimab, to market.&nbsp;Novo Nordisk said it plans to start a global phase 3 study of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH) and explore its use in other rare conditions. The deal is expected to close by late 2025.On Stocktwits, retail sentiment for Omeros was ‘extremely bullish’ amid ‘extremely high’ message volume, while sentiment for Novo Nordisk was ‘extremely bearish’ with ‘low’ message volume.One user on Stocktwits said the royalties from the Novo Nordisk deal alone could be worth billions, adding that despite some short-seller claims, Omeros still has an impressive pipeline and plenty of funding to develop new drugs.&nbsp;<stembedurl>https://stocktwits.com/whatsgood75/message/632507728</stembedurl>Another user said they had done their own research and believe the company is waiting on FDA decisions for other promising treatments, calling Omeros a solid firm with multiple revenue streams and saying they plan to buy more shares.<stembedurl>https://stocktwits.com/SnoddyTradz/message/632496306</stembedurl>While Omeros’ stock has risen 5% so far in 202, Novo Nordisk’s U.S.-listed stock has declined 33% over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside

The rally followed H.C. Wainwright’s price target hike to $20 on the back of a $2.1 billion licensing deal with Novo Nordisk for zaltenibart.

Equity

Danish drugmaker Novo Nordisk (NVO) on Wednesday said that it has entered into a definitive asset purchase and license agreement with Omeros Corporation (OMER) for its drug candidate Zaltenibart.Zaltenibart is in clinical development for rare blood and kidney disorders. Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916434">deal,</a> Novo Nordisk will be granted exclusive global rights to develop and commercialize Zaltenibart in all indications.Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales. Following the closing of the transaction, Novo intends to initiate a global late-stage program for Zaltenibart in paroxysmal nocturnal hemoglobinuria, a rare, acquired blood disorder where the body's immune system mistakenly attacks and destroys red blood cells. Omeros has already reported positive mid-stage data for Zaltenibart in treating the blood disorder.The transaction is expected to close in the fourth quarter of 2025. <a href="https://stocktwits.com/symbol/OMER">OMER shares</a> soared 136% in the pre-market session. On Stocktwits, retail sentiment around OMER jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.“Novo Nordisk is in a strong position to build on the work done by Omeros to maximize the value of this asset and develop Zaltenibart into a differentiated and potentially best-in-class treatment approach for a number of rare blood and kidney disorders,” said Martin Holst Lange, chief scientific officer and executive vice president of Research &amp; Development at Novo Nordisk.Omeros CEO Gregory A. Demopulos said that the company will now focus on securing approval and commercialization of Narsoplimab this quarter for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Novo, meanwhile, will also explore further development of Zaltenibart in a range of other rare blood and kidney disorders.OMER stock rose 7% this year, while NVO shares dropped 34%.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments.

Under the deal, Omeros will receive $340 million in upfront and near-term milestone payments and will be eligible to receive up to a total of $2.1 billion, including commercial milestone payments, in addition to tiered royalties on net sales.

Omeros Corporation has filed a marketing authorization application (MAA) with the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).The MAA is based on response-evaluable analyses of patients treated with narsoplimab and a comparison of overall survival with a well-matched external control group.&nbsp;According to the company, the submission shows a 61% response rate and a three-fold improvement in overall survival in the narsoplimab cohort.&nbsp;It also incorporates outcomes from over 130 patients treated under Omeros’ expanded access program.Following the news, H.C. Wainwright reiterated a ‘Buy’ rating and $9 price target on the stock.&nbsp;Analyst Brandon Folkes wrote that the EMA submission supports the view that Omeros “may be entering a phase of rerating” over the next 12 months, driven by potential U.S. approval, EU approval, and renewed appreciation for the broader pipeline.&nbsp;The firm expects narsoplimab to secure regulatory clearance in both regions, creating “significant value” for the company.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Retail investors voiced concerns after Omeros Corporation’s June 27 shareholder meeting, during which audio reportedly cut out during two critical questions on the company's regulatory outlook.One user claimed that approximately 80 seconds of the meeting, covering responses to questions about the status of the biologics license application (BLA) and the FDA’s ability to meet its PDUFA timeline, were missing from both the live broadcast and its replay.&nbsp;<stembedurl>https://stocktwits.com/WinstonWolfff/message/619393411</stembedurl>“We, as shareholders, deserve to hear the complete responses,” they wrote, adding that Omeros has “a HUGE shareholder relations/communication problem.”Another investor said they emailed Omeros directly, describing the audio loss during the “most important two questions regarding FDA approval” as “beyond embarrassing.”&nbsp;<stembedurl>https://stocktwits.com/TRYII/message/619392905</stembedurl>The user called for a full update and transcript, writing: “Please do the right thing here… Many, many investors are asking and suspicious.”<a href="https://stocktwits.com/symbol/OMER">Omeros'</a> stock has declined 67.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost

The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros first-in-class monoclonal antibody inhibiting the...

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings the Transplantation & Cellular Therapy...

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings the Transplantation & Cellular Therapy Meetings of the American Society for...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

OMER
Omeros Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OMER News

OMEROmeros Corporation